Aimee Black
Public Communications Contact presso Omega Fund Management LLC
Provenienza dei contatti di primo grado di Aimee Black
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
Omega Fund Management LLC
 Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US.
22
| Private Company | Investment Managers | 22 |
University of Otago
10
| College/University | Other Consumer Services | 10 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Aimee Black tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
Aerium Therapeutics, Inc.
 Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member Chairman | |
Nuvation Bio Operating Co., Inc.
 Nuvation Bio Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Nuvation Bio Operating Co., Inc. engages in the provision of biotechnology company developing proprietary therapies focuse on oncology. It portfolio includes Seven Novel and Mechanistically Distinct Oncology Programs, Each with Multiple Drug Development Candidates. The company was founded by David Hung in 2018 and is headquartered in New York, NY. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| OMEGA ALPHA SPAC | Financial Conglomerates | Founder Chief Executive Officer Founder Founder | |
| NeoMed S.à.r.l. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
| KRONOS BIO, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Corporate Officer/Principal Director of Finance/CFO | |
Danish BioVenture General Partner ApS
 Danish BioVenture General Partner ApS Financial ConglomeratesFinance Danish BioVenture General Partner ApS operates as a general partner and renders investment advice to K/S Danish BioVenture. It manages the administration and acts as a representative of Danish BioVenture in external commercial relations. The company was founded on June 26, 2009 and is headquartered in Copenhagen, Denmark. | Financial Conglomerates | Corporate Officer/Principal Corporate Officer/Principal | |
NRG Therapeutics Ltd.
 NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| University of Pavia | College/University | Graduate Degree Doctorate Degree | |
Chord Therapeutics SA
 Chord Therapeutics SA BiotechnologyHealth Technology Chord Therapeutics SA is a clinical stage pharmaceutical company. It develops drugs for patients with rare, life-threatening and severely disabling diseases. The firm offers CRD1. The company was founded by Arthur Roach and is headquartered in Geneva, Switzerland. | Biotechnology | Chairman Director/Board Member | |
Andrew Alliance SA
 Andrew Alliance SA Industrial MachineryProducer Manufacturing Andrew Alliance SA develops liquid handling solutions. Its product, Andrew, is a novel liquid handling robot designed for pipetting process. The firm's products include Andrew models, consumable dominos, protocol design, and enabling accessories. The company was founded by Piero Zucchelli, Giorgio Horak, and Antoine Jordan in March 2011 and is headquartered in Vernier, Switzerland. | Industrial Machinery | Director/Board Member Director/Board Member | |
| TREVI THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| GOSSAMER BIO, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| University of Geneva | College/University | Doctorate Degree Doctorate Degree | |
| Auckland University | College/University | Graduate Degree Undergraduate Degree | |
| Harvard Business School | College/University | Masters Business Admin Graduate Degree | |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Director of Finance/CFO Private Equity Investor | |
Cure Ventures Management LP
 Cure Ventures Management LP Investment ManagersFinance Cure Ventures Management LP (Cure Ventures) is a venture capital firm founded in 2021 by David R Fallace, Richard J Lim and Lou A Tartaglia. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Founder Private Equity Investor | |
| Orbimed Advisors Private Equity/UK/ | Investment Managers | Private Equity Investor | |
Attenua, Inc.
 Attenua, Inc. Pharmaceuticals: MajorHealth Technology Attenua, Inc. engages in the provision of biopharmaceutical services. The company was founded by Jing Liang and is headquartered in San Mateo, CA. | Pharmaceuticals: Major | Director/Board Member | |
TopiVert Ltd.
 TopiVert Ltd. BiotechnologyHealth Technology TopiVert Ltd. develops topical treatments for inflammatory diseases of the eye and gut. Its application is used in the treatment of asthma, chronic obstructive pulmonary disease, and cystic fibrosis and other inflammatory diseases of the lungs. The company was founded by Eric Charles Meldrum in 2011 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member | |
| WILSON THERAPEUTICS AB | Pharmaceuticals: Major | Director/Board Member | |
Oxular Ltd.
 Oxular Ltd. BiotechnologyHealth Technology Oxular Ltd. engages in research and experimental development on biotechnology. The firm develops retinal treatments to access specific small spaces in the eye and to provide drug distribution to tissues involved in retinal diseases. The company was founded by Tom Cavanagh and Ronald K. Yamamoto in 2014 and is headquartered in Oxford, the United Kingdom. | Biotechnology | Director/Board Member | |
| THE MONKS INVESTMENT TRUST PLC | Investment Trusts/Mutual Funds | Director/Board Member | |
Topivert Pharma Ltd.
 Topivert Pharma Ltd. Pharmaceuticals: MajorHealth Technology Topivert Pharma Ltd. is a British pharmaceutical company founded in 2011. The private company develops non-systemic medicines for the treatment of chronic inflammatory diseases of the gastrointestinal. | Pharmaceuticals: Major | Director/Board Member | |
| IMAGO BIOSCIENCES, INC. | Biotechnology | Director/Board Member | |
| SPRUCE BIOSCIENCES, INC. | Biotechnology | Director/Board Member | |
Neomed Management (Jersey) Ltd.
 Neomed Management (Jersey) Ltd. Investment ManagersFinance Neomed Management (Jersey) Ltd. is an investment firm invests in innovative healthcare and life science companies. The company is headquartered in St. Helier, the United Kingdom. | Investment Managers | Corporate Officer/Principal | |
| Oxular Acquisitions Ltd. | Director/Board Member | ||
Anjarium Biosciences AG
 Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | Biotechnology | Director/Board Member | |
Invest Europe
 Invest Europe Investment ManagersFinance Invest Europe is a Belgian company that operates as a private equity, venture capital and infrastructure investment company. The company is based in Brussels, Belgium. | Investment Managers | Director/Board Member | |
IFM Continua, Inc.
 IFM Continua, Inc. BiotechnologyHealth Technology IFM Continua, Inc. engages in the provision of biotechnology services. The company is headquartered in Boston, MA. | Biotechnology | Director/Board Member | |
IFM Cinque, Inc.
 IFM Cinque, Inc. Miscellaneous Commercial ServicesCommercial Services IFM Cinque, Inc. is a biotechnology company. The company is headquartered in Boston, MA. | Miscellaneous Commercial Services | Director/Board Member | |
OrbiMed Advisors Private Equity
 OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Investment Managers | Private Equity Investor | |
IFM Quattro, Inc.
 IFM Quattro, Inc. Miscellaneous Commercial ServicesCommercial Services IFM Quattro, Inc. is a biotechnology company. The company is headquartered in Boston, MA. | Miscellaneous Commercial Services | Director/Board Member | |
Sofinnova Investments, Inc.
 Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Investment Managers | Private Equity Investor | |
Oxford Bioscience Partners
 Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners is an Independent Venture Capital firm founded in 1992 by Edmund Martin Olivier, Alan G. Walton and Cornelius T. Ryan. The firm is headquartered in Boston. | Investment Managers | Director of Finance/CFO | |
| University of Cambridge | College/University | Undergraduate Degree | |
Avitide, Inc.
 Avitide, Inc. BiotechnologyHealth Technology Avitide, Inc. develops affinity purification solutions. Its technology enables development of chromatography resins via chemical synthesis which are not based on costly recombinant proteins. The company was founded by Errik B. Anderson, Warren Kett, Tillman U. Gerngross, Kevin Isett and Jonathan Sheller in 2012 and is headquartered in Lebanon, NH. | Biotechnology | Director/Board Member | |
| Erasmus University Rotterdam | College/University | Masters Business Admin |
Statistiche
Distribuzione geografica
| Stati Uniti | 24 |
| Regno Unito | 11 |
| Svizzera | 9 |
| Italia | 3 |
| Danimarca | 2 |
Settori
| Health Technology | 21 |
| Finance | 16 |
| Consumer Services | 8 |
| Commercial Services | 6 |
| Producer Manufacturing | 2 |
Posizioni
| Director/Board Member | 159 |
| Corporate Officer/Principal | 53 |
| Private Equity Investor | 45 |
| Independent Dir/Board Member | 30 |
| Undergraduate Degree | 28 |
Contatti più connessi
| Insiders | |
|---|---|
| Michael Powell | 48 |
| John Maraganore | 38 |
| Otello Stampacchia | 37 |
| Claudio Nessi | 25 |
| Dina Chaya | 23 |
| Vincent Ossipow | 22 |
| Bernard Davitian | 19 |
| Richard Lim | 17 |
| Roshawn Blunt | 14 |
| Michelle Doig | 12 |
| Anne-Mari Paster | 10 |
| Francesco Draetta | 9 |
| Deirdre Cunnane | 9 |
| Alexia Pearsall | 7 |
| Sanjaya Singh | 6 |
- Borsa valori
- Insiders
- Aimee Black
- Connessioni Società
